Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ORGO - Organogenesis Holdings Inc.


IEX Last Trade
3.18
0.330   10.377%

Share volume: 0
Last Updated: Tue 24 Dec 2024 06:15:53 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 35.29%

PREVIOUS CLOSE
CHG
CHG%

$2.85
0.33
11.58%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
22%
Profitability 18%
Dept financing 13%
Liquidity 39%
Performance 25%
Company vs Stock growth
vs
Performance
5 Days
4.26%
1 Month
-21.29%
3 Months
14.80%
6 Months
27.20%
1 Year
-19.70%
2 Year
27.71%
Key data
Stock price
$3.18
P/E Ratio 
-23.08
DAY RANGE
$2.85 - $3.22
EPS 
-$0.12
52 WEEK RANGE
$2.35 - $4.70
52 WEEK CHANGE
-$24.47
MARKET CAP 
381.816 M
YIELD 
N/A
SHARES OUTSTANDING 
132.575 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
2.05
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$749,048
AVERAGE 30 VOLUME 
$986,989
Company detail
CEO: Gary S. Gillheeney
Region: US
Website: organogenesis.com
Employees: 950
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Organogenesis Holdings Inc. develops, manufactures, and commercializes solutions for the advanced wound care, surgical and sports medicine markets in the United States. The company's products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved. NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; NuShield is a wound-covering tissue. NuCel is a dehydrated placental tissue surgically applied to the target tissue to support native healing. Nu

Recent news